Feedback
Settings

Settings

Goto Application

1. WO2017027898 - NOVEL CANCER TREATMENT INVOLVING MODULATION OF IL-3 ACTIVITY

PermaLink
Publication Number WO/2017/027898
Publication Date 23.02.2017
International Application No. PCT/AU2015/000720
International Filing Date 26.11.2015
IPC
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
G01N 33/48 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
G01N 33/574 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61P 35/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
04specific for metastasis
C07K 16/244
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
244Interleukins [IL]
C07K 16/2866
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2866against receptors for cytokines, lymphokines, interferons
C07K 2317/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
24containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
C07K 2317/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applicants
  • UNIVERSITY OF SOUTH AUSTRALIA [AU]/[AU]
  • CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC. [AU]/[AU]
Inventors
  • LOPEZ, Angel, F.
  • BONDER, Claudine, S.
  • THOMPSON, Emma
Agents
  • MADDERNS PATENT & TRADE MARK ATTORNEYS
Priority Data
201590332918.08.2015AU
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) NOVEL CANCER TREATMENT INVOLVING MODULATION OF IL-3 ACTIVITY
(FR) NOUVEAU TRAITEMENT DU CANCER METTANT EN ŒUVRE LA MODULATION DE L'ACTIVITÉ IL-3
front page image
Abstract
(EN)
A method of treating or preventing breast cancer (eg invasive ductal carcinoma) and/or cancer associated with elevated levels of either one or both of the IL-3 receptor (IL-3R) and interleukin-3 (IL-3) is discl osed which comprises administering to a subject an IL-3 -inhibiting agent such as an agent which inhibits (eg by blocking) IL-3R.
(FR)
La présente invention concerne un procédé de traitement ou de prévention d'un cancer du sein (par exemple un carcinome canalaire invasif) et/ou d'un cancer associé à des taux élevés de l'un ou l'autre ou les deux parmi le récepteur d'IL-3 (IL-3R) et l'interleukine-3 (IL-3) qui comprend l'administration à un sujet d'un agent inhibiteur d'IL-3 tel qu'un agent qui inhibe (par exemple, par blocage) IL-3R.
Also published as
AU2015406165
AU2015903329
US20190112378
Latest bibliographic data on file with the International Bureau
# -